Navidea Biopharmaceuticals Stock Price, News & Analysis (NYSE:NAVB) $0.07 +0.02 (+40.08%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.05▼$0.0750-Day Range$0.03▼$0.1052-Week Range$0.02▼$0.35Volume683,670 shsAverage Volume338,672 shsMarket Capitalization$7.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media About Navidea Biopharmaceuticals Stock (NYSE:NAVB)Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Read More NAVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAVB Stock News HeadlinesDecember 1, 2023 | msn.comNavidea settles litigation with Capital Royalty, stock rallies 30%December 1, 2023 | markets.businessinsider.comNavidea Biopharmaceuticals, CRG Settle All Ongoing LitigationDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 30, 2023 | americanbankingnews.comNavidea Biopharmaceuticals (NYSE:NAVB) Receives New Coverage from Analysts at StockNews.comNovember 1, 2023 | morningstar.comNavidea Biopharmaceuticals Inc NAVBOctober 26, 2023 | investing.comNavidea Biopharmaceuticals faces delisting from NYSE American, plans to move to OTC marketsOctober 6, 2023 | bizjournals.comNYSE American halts trading on Navidea stock after delisting recommendedOctober 5, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 5, 2023 | tmcnet.comNYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)August 10, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing PanelAugust 1, 2023 | finance.yahoo.comNYSE American starts to delist Navidea stock, company to appealJuly 31, 2023 | benzinga.comWhy Navidea Biopharmaceuticals Shares Are NosedivingJuly 31, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces OpportunitiesJuly 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American DeterminationJuly 28, 2023 | businesswire.comNYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)July 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial OfficerJuly 13, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps DownJuly 6, 2023 | bizjournals.comDublin biotech proposes reverse stock split, stock-for-debt swapJune 30, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain AssetsJune 16, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common StockJune 16, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone PaymentJune 7, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateJune 2, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Receives NYSE American NoticeMay 22, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at MarketMay 15, 2023 | investing.comNavidea Biopharma (NAVB) Earnings Dates & ReportsMay 11, 2023 | msn.comNavidea promotes Michael Sherman Blue to CMO postSee More Headlines Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNYSE:NAVB CUSIPN/A CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,180,000.00 Net MarginsN/A Pretax Margin-860,700.00% Return on EquityN/A Return on Assets-166.65% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.51 Sales & Book Value Annual Sales$70,000.00 Price / Sales99.94 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-2.33Miscellaneous Outstanding Shares100,080,000Free Float56,367,000Market Cap$7.00 million OptionableOptionable Beta1.54 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Craig A. Dais CPA (Age 57)CFO & Principal Accounting Officer Dr. Michael Sherman Blue F.A.C.E.P.M.D., Chief Medical OfficerKey CompetitorsVirax Biolabs GroupNASDAQ:VRAXMyMD PharmaceuticalsNASDAQ:MYMDBiomericaNASDAQ:BMRATrinity BiotechNASDAQ:TRIBiSpecimenNASDAQ:ISPCView All Competitors NAVB Stock Analysis - Frequently Asked Questions How have NAVB shares performed in 2023? Navidea Biopharmaceuticals' stock was trading at $0.21 at the beginning of 2023. Since then, NAVB shares have decreased by 66.7% and is now trading at $0.0699. View the best growth stocks for 2023 here. How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced its earnings results on Tuesday, November, 14th. The company reported ($0.02) EPS for the quarter. Who are Navidea Biopharmaceuticals' major shareholders? Navidea Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:NAVB) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.